{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:58:44Z","timestamp":1762376324847,"version":"3.41.2"},"reference-count":38,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100006315","name":"Reumafonds","doi-asserted-by":"publisher","award":["9-1-201"],"award-info":[{"award-number":["9-1-201"]}],"id":[{"id":"10.13039\/501100006315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.01377","type":"journal-article","created":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T03:23:03Z","timestamp":1508901783000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis"],"prefix":"10.3389","volume":"8","author":[{"given":"Christien","family":"Rondaan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kornelis S. M.","family":"van der Geest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Eelsing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemieke M. H.","family":"Boots","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaas A.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Westra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,10,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0140-6736(06)69561-5","article-title":"Varicella","volume":"368","author":"Heininger","year":"2006","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/msc.175","article-title":"A literature review regarding the management of varicella-zoster virus","volume":"8","author":"Bond","year":"2010","journal-title":"Musculoskeletal Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1503\/cmaj.091711","article-title":"The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study","volume":"182","author":"Drolet","year":"2010","journal-title":"CMAJ"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/j.vaccine.2012.01.045","article-title":"Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study","volume":"30","author":"Drolet","year":"2012","journal-title":"Vaccine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/2051013615599151","article-title":"Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective","volume":"3","author":"Johnson","year":"2015","journal-title":"Ther Adv Vaccines"},{"key":"B8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/rheumatology\/kew273","article-title":"The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease","volume":"56","author":"Dejaco","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/acr.2262","article-title":"Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease-modifying antirheumatic drugs","volume":"67","author":"Pappas","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrrheum.2014.206","article-title":"Vaccination of patients with autoimmune inflammatory rheumatic diseases","volume":"11","author":"Westra","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1056\/NEJMct066061","article-title":"Varicella-zoster vaccine for the prevention of herpes zoster","volume":"356","author":"Kimberlin","year":"2007","journal-title":"N Engl J Med"},{"key":"B16","first-page":"CE2","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"70","author":"van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1016\/j.vaccine.2015.04.090","article-title":"Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic\/maintenance corticosteroids","volume":"33","author":"Russell","year":"2015","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1002\/art.38625","article-title":"Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica","volume":"66","author":"van der Geest","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/rheumatology\/keu526","article-title":"Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica","volume":"54","author":"van der Geest","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"672","DOI":"10.7326\/0003-4819-97-5-672","article-title":"Polymyalgia rheumatica: a 10-year epidemiologic and clinical study","volume":"97","author":"Chuang","year":"1982","journal-title":"Ann Intern Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1002\/art.38804","article-title":"Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases","volume":"66","author":"Rondaan","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1002\/art.24679","article-title":"Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus","volume":"60","author":"Holvast","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/jmv.24629","article-title":"Relationship between cell-mediated immunity to Varicella-Zoster virus and aging in subjects from the community-based Shozu Herpes Zoster study","volume":"89","author":"Shirane","year":"2017","journal-title":"J Med Virol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1086\/379048","article-title":"Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine","volume":"188","author":"Levin","year":"2003","journal-title":"J Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1128\/CMR.00052-13","article-title":"Pathogenesis and current approaches to control of varicella-zoster virus infections","volume":"26","author":"Gershon","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jim.2003.09.001","article-title":"Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells","volume":"283","author":"Karlsson","year":"2003","journal-title":"J Immunol Methods"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1093\/rheumatology\/keq200","article-title":"Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study","volume":"49","author":"Schafer","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1017\/S0022172400025730","article-title":"Specific immunoglobulin responses after varicella and herpes zoster","volume":"82","author":"Cradock-Watson","year":"1979","journal-title":"J Hyg (Lond)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/infdis\/jiu500","article-title":"Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection","volume":"211","author":"Schub","year":"2015","journal-title":"J Infect Dis"},{"key":"B32","first-page":"2572","article-title":"Detection of varicella zoster virus DNA in some patients with giant cell arteritis","volume":"42","author":"Mitchell","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jns.2013.09.034","article-title":"Varicella zoster virus in the temporal artery of a patient with giant cell arteritis","volume":"335","author":"Nagel","year":"2013","journal-title":"J Neurol Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1001\/jamaneurol.2015.2101","article-title":"Analysis of varicella-zoster virus in temporal arteries biopsy positive and negative for giant cell arteritis","volume":"72","author":"Nagel","year":"2015","journal-title":"JAMA Neurol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0022-510X(03)00167-9","article-title":"Absence of detection of varicella-zoster virus DNA in temporal artery biopsies obtained from patients with giant cell arteritis","volume":"215","author":"Kennedy","year":"2003","journal-title":"J Neurol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1002\/art.38631","article-title":"In search of a candidate pathogen for giant cell arteritis: sequencing-based characterization of the giant cell arteritis microbiome","volume":"66","author":"Bhatt","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/ard.2004.025320","article-title":"Human parvovirus B19, varicella zoster virus, and human herpes virus 6 in temporal artery biopsy specimens of patients with giant cell arteritis: analysis with quantitative real time polymerase chain reaction","volume":"64","author":"Alvarez-Lafuente","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1136\/annrheumdis-2016-210152","article-title":"Infections and the risk of incident giant cell arteritis: a population-based, case-control study","volume":"76","author":"Rhee","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01377\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T03:23:06Z","timestamp":1508901786000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01377\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,24]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2017.01377"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.01377","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2017,10,24]]},"article-number":"1377"}}